H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Climb Bio (CLYM) with a Buy rating and $9 price target The firm views Climb Bio as a “disruptive innovator” in the field of B cell-mediated autoimmune diseases. Comparable valuations “hint at considerable upside potential” for the shares, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: